Another study showed that different thresholds of Smad3 activation control TGF-β responses in hepatocytes and that liver cancer-derived HCV core protein, by decreasing Smad3 activation, switches TGF-β growth inhibitory effects to tumor-promoting responses [123]. Here, SMAD3 is linked to liver cancer.